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IT HAS BEEN SHOWN that certain cyto-
toxic agents may be combined in such a
way as to reduce normal-tissue toxicity
(Millar & McElwain, 1978; Millar et al.,
1978a,b; Hedley et al., 1978). Such com-
binations take the form of a small pre-
treatment or "priming" dose of chemo-
therapeutic agent (usually cyclophosph-
amide, melphalan or cytosine arabinoside)
followed at a fixed time by a large
"challenge" dose of an alkylating agent
or whole-body irradiation. The mechanism
underlying this effect is not known.
A key question is whether tumours are
similarly protected. In curability experi-
ments conducted with Lewis lung carcin-
oma (Millar & McElwain, 1978) a com-
bination which protected normal tissue
(small dose cyclophosphamide (CY) 4 days
before large-dose CY) didnot spare tumour
tissue. In the light of these findings we
wondered whether the phenomenon could
be used in tumours sensitive to the pre-
treatment agent to increase still further
the anti-tumour effect whilst maintaining
normal-tissue protection, and thus further
improving the therapeutic index. This
communication reports experiments in
which we found that priming treatments
not only protected against toxicity but
also increased the anti-tumour effect.
Eight to 10-week-old C57BL male mice
were used throughout. Five animals were
used per group and in both experiments
the animals were implanted bilaterally
with tumour.
The tuimour used was the FS6 fibro-
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sarcoma, which was chemically induced
and routinely passaged at this Institute.
This tumour was found to be sensitive to
cy. Tumours for transplantation, measur-
ing about 1 cm3, were cut into pieces
2 x 2 mm, washed in saline and dis-
aggregated for 1' h in Medium 199 (Flow
Laboratories) containing 0.1% trypsin
(Flow Laboratories), 0-01% DNAse
(Sigma) and 0-1 I collagenase (Boehringer
Mannheim) at 30°C. The resulting suspen-
sion was washed in medium containing
0.01% DNAse (to prevent clumping) and
1.5 x 107 cells were injected s.c. into each
animal in 01ml suspension. Treatment
started after 15 days, when the tumours
were, on average, 1 cm3.
The end-point was tumour growth delay
after treatment. Tumour volumes were
calculated by measuring the greatest
diameter (L) and the diameter perpendicu-
lar to the greatest diameter (D) and then
applying the formula V= -rLD2/6. The
growth rates of individual tumours were
measured by comparing the volume at
time t (Vt) with the pre-treatment volume
(VO). The value Vt/V0 was calculated for
each tumour at each sampling time, and
a mean and standard error then calculated
for each sampling time point from animals
for each treatment group. Growth delay
was calculated as the difference between
treated and control tumours in time to
reach twice the pre-treatment volume.
All drugs were administered i.p. Pure
cyclophosphamide monohydrate (CY)
(Endoxana, Koch-Light Ltd) was usedJ. L. MILLAR, R. D. CLUTTERBUCK AND I. E. SMITH
dissolved in saline. Melphalan (Melph)
(Alkeran, Burroughs WN'ellcome & Co.) was
first dissolved in 1 ml of 2O% (v/v) acid
alcohol and then in saline to the required
concentration. Both solutions were pre-
pared shortly before use.
In the first experiment animals were
(a) left untreated, (b) treated with 300 mg/
kg CY alone, (c) given 50 mg/kg CY 4 days
before 300 mg/kg CY, or (d) given 100 mg/
kg 4 days before 300 mg/kg CY. Four days
had previously been shown to be the
optimum interval in mice for decreasing
normal-tissue toxicity, thus enhancing
survival for this combination (Millar &
McElwain, 1978). All animals treated with
300 mg/kg CY alone died 3-14 days after
treatment; tumour was present, in all of
them but was not the cause of death. No
animals died which had been pre-treated
with either 50 or 100 mg/kg CY 4 days
before 300 mg/kg.
In the second experiment melphalan
was given as the challenge agent at 1a mg/
kg. CY was given as a pre-treatment at
2 dose levels, 50 or 100 mg/kg. The CY
was given on Day 0 and melphalan on
Day 2, as this is the time interval giving
greatest protection of normal tissues with
this combination (Millar et al., 1978a).
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FiG. l. Response of F56 tumouir to high-dose
cyclophosphami(le (CY) pre-treatment.
Vt/Vo is the mean ratio of tuLmour volume
to pre-treatment volume. The pre-treat-
mentX was given on Day 0 ain(l the challenge
on Day 4 (arrows). (A) Untreated cointrols.
(0) 300 mg/kg CY on I)ay 4 alone. All
animals dead by Day 18. (A) 300 mg/kg CY
on Day 4, pre-treatedl witlh 50 mg/kg CY on
IDay 0. (0) 300 mg/kg CY on Day 4, pre-
t-eatcdl with 100 mg/kg CY on Day 0.
Fig. 1 shows the effect of the various
treatments on tumour growth delay. In
the group of animals treated with 300 mg/
kg CY alone, 3 animals died on Day 7, a
4th on Day 16 and the last on Day 18. A
growth delay of 16 days was estimated,
though in view of the mortality this value
must be regarded with caution. Animals
pre-treated with 50 mg/kg CY before 300
mg/kg cy all survived, as did the animals
given 100 mg/kg CY before 300 mg/kg CY,
and growth delays of 32 and 40 days
respectively were measured. No complete
regressions were seen in any of the groups.
In the second experiment, melphalan on
its own produced a growth delay of 12
days (Fig. 2); 50 mg/kg CY before this dose
of melphalan produced a growth delay of
26 days, and a growth delay of 33 days
was obtained with 100 mg/kg CY as the
pre-treatment.
These studies demonstrate that in this
system CY pre-treatment had a normal-
tissue sparing effect reflected in enhanced
animal survival, but no such sparing effect
on the tumour itself. On the contrary
the pre-treatment dose of CY appeared
to have a positive anti-tumour effect, in
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FIcG. 2.-Response of FS6 ttumouir to lighi-
(lose melplialan writhi or w'ithloult CY pre-
treatment. Vt/V0 is thie mean ratio of
ttumour voltme to pre-treatment x oltune.
The pre-treatment (lose was givren on D)ay 0
an(l the challenge on Day 2 (arrows).
(A) Untreate(d controls. (0) 15 mg/kg
melphalan oi D)ay 2 alone. (A) 15 mg/kg
melphalan on Day 2, pre-treated with 50
mg/kg CY on Day 0. (0) 15mg/kg melpli-
alan on Day 2, pre-treate(i witlh 100 mg/kg
CY oi t)ay 0.
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that tumour growth delay was increased;
furthermore, the results suggest that this
anti-tumour effect could be increased by
increasing the pre-treatment dose of CY.
The improvement in the therapeutic
ratio of CY when given in this way has
interesting clinical implications. Hedley
et al. (1978) have already shown that
peripheral-leucocyte recovery in patients
with malignant melanoma treated with
high-dose melphalan can be enhanced by
CY pre-treatment. However, there appears
to be little likelihood in an extremely
chemoresistant tumour such as melanoma,
of a significant clinical anti-tumour effect
with the pre-treatment itself. In contrast,
small-cell carcinoma of the lung is fre-
quently clinically responsive to CY.
Clinical studies have therefore begun in
such patients to test whether the results
obtained with CY pre-treatment against
the FS6 mouse sarcoma can be repeated in
man. Further laboratory studies are also
under way to investigate the phenomenon
both with cyclophosphamide and other
agents.
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